Your cart is empty.
Zurich, Switzerland, 26 April 2002 – Tecan, a leading player in the fast-growing Life Science supply industry, today held its Annual General Meeting at the Casino Zürichhorn close to its headquarters in Männedorf. At the meeting, the proposal by the Board of Directors to pay a dividend of CHF 0.45 per share, a 29% increase from last year’s dividend of CHF 0.35, was approved. Shareholders also supported the re-election of all current members of the Board of Directors and approved the company’s business reports for the financial year 2001.
Emile Sutcliffe, CEO of the Tecan Group, commented: ”Despite unfavourable market conditions last year, Tecan was able to build further on its record financial performance of 2000. In line with our company policy, we continue to deliver the benefits of our growth and financial success to all Tecan shareholders.”
In 2001, Tecan reported worldwide sales of CHF 361.9 million, an increase of 32.3% compared to CHF 273.5 million in 2000. Compared to the record financial performance of 2000, Tecan further accelerated its sales growth in local currencies to 35% (2000: 33%) despite turbulent market conditions last year. On 12 April, the company announced that it will report worldwide sales of CHF 85.3 million for the first quarter of 2002, compared with CHF 84.3 million in the first three months of 2001. Full details of the first quarter results will be reported on April 30.
At the Annual General Meeting, shareholders also approved the business report for 2001 including the annual report, annual financial statements, and consolidated financial statements for the year.
Board of Directors
Shareholders were also asked to re-elect the proposed members of the Board of Directors. The re-appointments of Mr. Mike Baronian, Prof. Dr Armin Seiler, Dr Emile Sutcliffe, and Messrs. Timothy B. Anderson and Hans-Joerg Kummer as directors for a new statutory mandate of 1 year were approved.
Tecan (www.tecan.com) is a leading player in the fast growing Life Sciences supply industry that specializes in the development, production, and distribution of solutions enabling the discovery of pharmaceutical substances, as well as for genomics, proteomics, and diagnostics. Tecan clients are leading pharmaceutical and biotechnology companies, university research departments and diagnostic laboratories. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both North America and Europe and maintains a sales and service network in 52 countries. In 2001, Tecan achieved sales of CH 361.9 million (USD 214.1 million; EUR 239.6 million). Registered shares of Tecan Group are traded on the Swiss SWX stock exchange (TK: TECN / Reuters: TECZn.S / Valor : 1210019).
Rochat & Partners:
Rochat & Partners
Tel.: +41 (0)22 786 54 55
Fax: +41 (0)22 786 54 58